University of Groningen
Studies on Ligand Directed Enzyme Prodrug Therapy and Production of Long Acting Protein Therapeutics for Targeted Cancer Treatment
Al-Mansoori, Layla
DOI:
10.33612/diss.131689831
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Al-Mansoori, L. (2020). Studies on Ligand Directed Enzyme Prodrug Therapy and Production of Long Acting Protein Therapeutics for Targeted Cancer Treatment. University of Groningen.
https://doi.org/10.33612/diss.131689831
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Studies on Ligand Directed
Enzyme Prodrug Therapy and
Production of Long Acting Protein
Therapeutics for Targeted Cancer
Treatment
The research described in this thesis was conducted in the Protein Engineering Lab, Research Department, at Anti-doping Laboratory Qatar (ADLQ). The work was financially supported by Qatar National Research Fund (QNRF) NPRP60653012 and Qatar University (QU), Doha -Qatar.
The author gratefully thanks QNRF and QU for funding part of this work, and University Medical Center Groningen (UMCG) and ADLQ for facilitating the research.
Cover design and layout: picture obtained from
https://www.cancercenter.com/community/blog/2018/02/how-does-cancer-do-that-cancer-cells-find-ways-to-resist-treatmentand modified by Layla Al-Mansoori.
Printed by: Aspire Printing Press / Qatar.
© Copyright 2020, Layla Al-Mansoori. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission of the author.
Studies on Ligand Directed
Enzyme Prodrug Therapy and
Production of Long Acting
Protein Therapeutics for
Targeted Cancer Treatment
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the
Rector Magnificus Prof. C. Wijmenga and in accordance with
the decision by the College of Deans. This thesis will be defended in public on Monday 14th September 2020 at 09.00 hours
by
Layla Al-Mansoori
born on 17 September in Doha-Qatar
Studies on Ligand Directed
Enzyme Prodrug Therapy and
Production of Long Acting
Protein Therapeutics for
Targeted Cancer Treatment
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the
Rector Magnificus Prof. C. Wijmenga and in accordance with
the decision by the College of Deans. This thesis will be defended in public on Monday 14th September 2020 at 09.00 hours
by
Layla Al-Mansoori
born on 17 September in Doha-Qatar 1974
Supervisors
Prof. P.H. Elsinga Prof. S.K. GodaAssessment Committee
Prof. A.S.S. DömlingProf. F. Kuipers Prof. L. Chouchane
Supervisors
Prof. P.H. Elsinga Prof. S.K. GodaAssessment Committee
Prof. A.S.S. DömlingProf. F. Kuipers Prof. L. Chouchane
Table of Content
Chapter 1:
General Introduction of Thesis.……….………..…..7Chapter 2:
Studies on Ligand Directed Enzyme Prodrug Therapy & Production of Long-Acting Protein Therapeutics for Targeted Cancer Treatment………...17Chapter 3:
………..……..75Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment.
Chapter 4:
………..………..………115In vitro studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy.
Chapter 5:
………..…...…151Production of long-acting CNGRC-CPG2 fusion proteins: New derivatives to overcome drug immunogenicity of ligand directed enzyme prodrug therapy for targeted cancer treatment
